Media Articles Related to Covera-HS (Verapamil)
Could a common blood pressure drug completely reverse diabetes?
Source: Pharma Industry / Biotech Industry News From Medical News Today [2014.11.06]
Verapamil, a common blood pressure drug, has been shown to completely reverse diabetes in mice. Now, researchers are conducting a clinical trial to see if it works in humans.
Published Studies Related to Covera-HS (Verapamil)
Need for prophylactic application of verapamil in transradial coronary
procedures: a randomized trial. The VITRIOL (is Verapamil In TransRadial
Interventions OmittabLe?) trial. 
CONCLUSIONS: The preventive use of verapamil may be unnecessary for transradial
Identifying iatrogenic depression using confirmatory factor analysis of the Center for Epidemiologic Studies Depression Scale in patients prescribed a verapamil-sustained-release-led or atenolol-led hypertension treatment strategy. [2011.11.29]
BACKGROUND: beta-blockers and calcium channel blockers are highly effective medications indicated for treatment and prevention of hypertension. However, the literature regarding the potential depressive effects of beta-blockers and calcium channel blockers is equivocal regarding whether one or both are associated with depression. OBJECTIVES: To determine whether self-reported depressive symptoms of older persons with hypertension and coronary artery disease and who were randomly assigned to a verapamil-sustained-release-led (Ve-led) or atenolol-led (At-led) hypertension treatment strategy were similar using confirmatory factor analytical models of the Center for Epidemiologic Studies Depression Scale (CES-D)... CONCLUSIONS: The domains indicating less happiness and more depressive symptoms were most likely to be unfavorably impacted by the At-led treatment strategy. Given a choice between these equally effective high blood pressure treatment strategies, it may be prudent to use the Ve-led strategy. This is especially true if the risk of the occurrence of a mood-related side effect of the beta-blocker outweighs its other benefits in comparison. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. [2011.08]
Microdosing studies are effective in enabling the early identification of the pharmacokinetic properties of compounds administered to humans. However, the nonlinearity of the pharmacokinetics between microdose and therapeutic dose, attributable to the saturation of metabolic enzymes and transporters, is a major concern.
Trandolapril, but not verapamil nor their association, restores the physiological renal hemodynamic response to adrenergic activation in essential hypertension. [2011.06]
The purpose of this study was to evaluate the effects of antihypertensive drugs on renal hemodynamics in hypertensive patients during an adrenergic activation by mental stress (MS), which induces renal vasoconstriction in healthy subjects. Renal hemodynamics was assessed twice in 30 middle-aged essential hypertensive patients (57+/-6 years)-after 15 days of pharmacological wash-out and after 15 days of treatment with Trandolapril (T, 4 mg, n=10), Verapamil (V, 240 mg, n=10), or both (T 2 mg+V 180 mg, n=10)...
The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis. [2011.06]
OBJECTIVE: Verapamil and adenosine are the most common agents used to treat paroxysmal supraventricular tachycardia (PSVT). We performed a systematic review and meta-analysis to determine the relative effectiveness of these drugs and to examine their respective adverse effect profiles... CONCLUSION: Adenosine and verapamil have similar efficacy in treating PSVT. Adenosine has a higher rate of minor adverse effects, and of overall adverse effects, whereas verapamil has a higher rate of causing hypotension. A decision between the two agents should be made on a case-by-case basis and ideally involve informed discussion with the patient where appropriate.
Clinical Trials Related to Covera-HS (Verapamil)
Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers [Recruiting]
The purpose of this study is to evaluate the potential for a pharmacokinetic (PK) drug-drug
interaction between INX-08189 and extended release verapamil hydrochloride (verapamil HCL
The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers [Completed]
We, the researchers at the Indiana University School of Medicine, are doing this study to
better understand how the effects of certain medications are altered when taken
simultaneously, or in combination with each other. We will also look at how each volunteer's
genes (DNA) may affect the way these medications are metabolized.
We will test the hypothesis that the extent of drug-drug interaction caused by the
combination of erythromycin and diltiazem is not predictable from the extent of interaction
produced by each inhibitor alone. Specifically we will test the hypothesis that the
combination of erythromycin and diltiazem will cause a greater decrease in midazolam
intravenous and oral clearance than the sum of the decreases caused by each inhibitor alone.
Safety, Tolerability, and Efficacy of IA Verapamil in the Treatment of Joint Pain in Subjects With Osteoarthritis of the Knee [Recruiting]
This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the
safety, tolerability, and efficacy of Intra-Articular (IA) verapamil in the treatment of
joint pain in patients with knee osteoarthritis (OA). Subjects will discontinue all
analgesic medications for the entire duration of the study, except for acetaminophen (taken
on an as needed basis at no more than 2 g/day). At visit 2, subjects who meet all entry
criteria will be randomized to receive a single injection of IA verapamil or IA placebo at a
ratio of 1: 1. Treatments will be given with fluoroscopy or ultrasound to confirm needle
placement. Subjects will be monitored for blood pressure and heart rate (sitting and
standing) for at least 1 hour post-injection. Subjects will be evaluated at weeks 1, 2, 3,
4, 6, 8, and 12 after treatment.
Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers [Not yet recruiting]
This Study evaluates the possible drug interaction between FosD and verapamil when taken
Diltiazem Hydrochloride Cream for Anal Fissure [Recruiting]
A Phase III, multicentre, randomised, double blind, placebo-controlled study in subjects
having anal fissure (AF) with AF-related pain. Subjects will undertake a 1-week screening
period to provide baseline data and for assessment of eligibility. At the Baseline visit
(Week 0), eligible subjects (having an average Numerical Rating Scale (NRS) score of >4 for
worst pain associated with or following defaecation) will be randomised on a 1: 1:1 basis to
one of the three treatment groups. Subjects will receive diltiazem hydrochloride 2% cream
or diltiazem hydrochloride 4% cream or placebo cream. Study treatment will be applied in
and around the anus, three times daily, for up to 8 weeks. Following the Week 0 Visit,
subjects will be contacted by telephone during Week 1 to ensure adequate compliance with
study treatment, to ensure that study drug is being tolerated and that any concomitant
medications are used at a level consistent with that prior to randomisation. Subjects will
return to the clinic for safety and efficacy assessments at Weeks 2, 4, and 8 and receive a
follow-up telephone call at Week 12, following cessation of therapy.
Concomitant laxatives and stool softeners will be permitted, as needed, during the entire
study period (screening and treatment) to ensure that constipation or passage of hard stools
does not confound evaluation or improvement of the condition. Fibre supplements will be
allowed but should be continued at the baseline level.
Instructions on the use of the IVRS diary will be issued to subjects to record
fissure-related pain (NRS) and bowel symptoms daily during the 1-week screening period, to
confirm eligibility and post-randomisation to record worst anal pain associated with or
following defaecation (NRS) and daily overall AF-related pain (NRS). A record of the number
of times the subject has defaecated, laxative and analgesic usage will also be made as well
as the number of applications of study treatment, any changes to concurrent medications and
any Adverse Events (AEs).
In addition, at some or all study visits, subjects will record the Patient's Global
Impression of Improvement (PGI-I) on a 7 point Likert scale, complete a Short Form 36
(SF-36) quality of life questionnaire and will undergo examination of their AF. Routine
blood samples will be taken and the Skin Irritation Score (SIS) recorded for safety
Subjects may receive permitted medications for pain per Entry Criteria, but these should
remain stable, where possible, up to the Week 8 Visit. Introduction of any new medication
for AF will not be permitted unless the Investigator deems "rescue" intervention necessary.
A subject will be deemed a treatment failure if rescue intervention is required and will
have to be withdrawn from the study.
Any subject leaving the study following randomisation for any reason will be asked to
complete the Early Withdrawal Visit. This includes subjects who withdraw due to the
development of AEs or intolerance, as well as subjects who require rescue intervention.
These subjects will return for safety follow-up visits at their previously scheduled
follow-up assessment appointments. If complete healing has occurred at the 2 or 4 Week
visits, (i. e. prior to the end of the 8-week treatment period), subjects will be asked to
continue applying the medication for the full 8 week course, up to the final assessment.
Following the Week 8 visit (or Early Withdrawal Visit), subjects will be followed up for a
further 4 weeks (following cessation of study medication) to note any AEs.
All routine blood analyses (haematology and biochemistry) and plasma levels of diltiazem and
of its principal metabolites will be analysed by central laboratories.
Reports of Suspected Covera-HS (Verapamil) Side Effects
Joint Swelling (4),
Myocardial Infarction (2),
Angina Pectoris (2),
Intentional Overdose (1),
Completed Suicide (1),
Blood Pressure Inadequately Controlled (1),
Blood Cholesterol Increased (1), more >>